A Form 4 shows DHT Holdings director Erik Lind sold 30,000 shares at $22.46 apiece on September 15, leaving him with 132,294 shares.
DHT Holdings (DHT) director Erik Lind sold 30,000 common shares in an open-market transaction on September 15, according to a Form 4 filed with the Securities and Exchange Commission. The shares changed hands at $22.46 each, putting the combined value of the disposal at roughly $673,800.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.
